Table 1.
Patient characteristics of the study cohort
| Variable | Frequency | |
|---|---|---|
| n | % | |
| Gender | ||
| Male | 71 | 45.5 |
| Female | 85 | 54.5 |
| Age (y) | ||
| < 18 | 70 | 44.9 |
| ≥ 18 | 86 | 55.1 |
| CFTR genotype | ||
| F508del/F508del | 63 | 40.4 |
| F508del/G551D | 15 | 9.6 |
| F508del/other | 61 | 39.1 |
| Other/other | 17 | 10.9 |
| CF-related diabetesa | 58 | 37.2 |
| Mean ± SD | Median | |
|---|---|---|
| FEV1pp (n = 136 b) | 93.2 ± 27.0 | 98.0 |
| BMIc | 20.0 ± 3.9 | 20.1 |
Definition of abbreviations: y, years; CFTR, cystic fibrosis transmembrane conductance regulator; FEV1pp, forced expiratory volume in one second, percent predicted; BMI, body mass index; SD, standard deviation
aGlycosylated hemoglobin ≥ 6.5%, fasting plasma glucose ≥ 7 mmol/L, and/or 2-h oral glucose tolerance test (oGTT) plasma glucose ≥ 11 mmol/L.; bn is specified when data are missing (no measurements in children < 6 y); cweight classification of children according to S2 AGA 10/2015 guideline [6] using gender-specific age percentiles